Biotech co. can sue competitor over product claims 
By:
Eric T. Berkman
Published: December 26, 2012
Tags: biotech, false claims, Massachusetts, prescription drugs, press release
A biotech company could sue a competitor under the Lanham Act for distributing a press release that allegedly made false claims about a drug both companies manufactured and sold, a U.S. District Court in Massachusetts has ruled.
Federal Circuit ruling a win for biotech field
By:
Lisa Keen
Published: September 5, 2012
Tags: biotech, Federal Circuit, genetic testing, patent
In a second victory for the biotech industry in one year, the Federal Circuit has reinstated its ruling that a company’s isolation of human genetic material, and its process for using that material to determine the effectiveness of certain cancer therapies, meet the threshold test for patent-eligibility.
